IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse

Microbes and Infection

Volumn 8, Issue 14-15, 2006, Pages 2880-2889

  Zhou, Weisong ^a   Hashimoto, Koichi ^b   Moore, Martin L ^a   Elias, Jack A ^c   Zhu, Zhou ^d   Durbin, Joan ^e   Colasurdo, Giuseppe ^f   Rutigliano, John A ^g   Chiappetta, Constance L ^f   Goleniewska, Kasia ^a   O'Neal, Jamye F ^a   Graham, Barney S ^g   Stokes Peebles Jr , R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c YALE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

IL 13; Interferon; Virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GENE OVEREXPRESSION; HEP 2 CELL; HUMAN; HUMAN CELL; LUNG; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; INTERFERON TYPE II; INTERLEUKIN-13; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; STAT1 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

MUS MUSCULUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 33845522440     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.09.007     Document Type: Article

References (42)

1. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., and Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol. 72 (1998) 2871-2880
2. Johnson T.R., and Graham B.S. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73 (1999) 8485-8495
3. Openshaw P.J., Clarke S.L., and Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4 (1992) 493-500
4. Johnson T.R., Parker R.A., Johnson J.E., and Graham B.S. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol. 170 (2003) 2037-2045
5. Wynn T.A. IL-13 effector functions. Annu. Rev. Immunol. 21 (2003) 425-456
6. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., and Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science 282 (1998) 2258-2261
7. Peebles Jr. R.S., Hashimoto K., and Graham B.S. The complex relationship between respiratory syncytial virus and allergy in lung disease. Viral Immunol. 16 (2003) 25-34
8. Lukacs N.W., Tekkanat K.K., Berlin A., Hogaboam C.M., Miller A., Evanoff H., Lincoln P., and Maassab H. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. J. Immunol. 167 (2001) 1060-1065
9. Tekkanat K.K., Maassab H.F., Cho D.S., Lai J.J., John A., Berlin A., Kaplan M.H., and Lukacs N.W. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J. Immunol. 166 (2001) 3542-3548
10. Fischer J.E., Johnson J.E., Kuli-Zade R.K., Johnson T.R., Aung S., Parker R.A., and Graham B.S. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J. Virol. 71 (1997) 8672-8677
11. Barner M., Mohrs M., Brombacher F., and Kopf M. Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr. Biol. 8 (1998) 669-672
12. Urban Jr. J.F., Noben-Trauth N., Donaldson D.D., Madden K.B., Morris S.C., Collins M., and Finkelman F.D. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8 (1998) 255-264
13. Zheng T., Zhu Z., Wang Z., Homer R.J., Ma B., Riese Jr. R.J., Chapman Jr. H.A., Shapiro S.D., and Elias J.A. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J. Clin. Invest. 106 (2000) 1081-1093
14. McKenzie G.J., Emson C.L., Bell S.E., Anderson S., Fallon P., Zurawski G., Murray R., Grencis R., and McKenzie A.N. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9 (1998) 423-432
15. Durbin J.E., Johnson T.R., Durbin R.K., Mertz S.E., Morotti R.A., Peebles R.S., and Graham B.S. The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol. 168 (2002) 2944-2952
16. Graham B.S., Perkins M.D., Wright P.F., and Karzon D.T. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26 (1988) 153-162
17. Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., O'Hara Jr. R.M., Beier D.R., Turner K.J., Wood C.R., and Collins M. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161 (1998) 2317-2324
18. Rutigliano J.A., Rock M.T., Johnson A.K., Crowe Jr. J.E., and Graham B.S. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 337 (2005) 335-343
19. Homer R.J., Zheng T., Chupp G., He S., Zhu Z., Chen Q., Ma B., Hite R.D., Gobran L.I., Rooney S.A., and Elias J.A. Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am. J. Physiol. Lung Cell Mol. Physiol. 283 (2002) L52-L59
20. Montaner L.J., Doyle A.G., Collin M., Herbein G., Illei P., James W., Minty A., Caput D., Ferrara P., and Gordon S. Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J. Exp. Med. 178 (1993) 743-747
21. Montaner L.J., Bailer R.T., and Gordon S. IL-13 acts on macrophages to block the completion of reverse transcription, inhibit virus production, and reduce virus infectivity. J. Leukoc. Biol. 62 (1997) 126-132
22. Bailer R.T., Lee B., and Montaner L.J. IL-13 and TNF-alpha inhibit dual-tropic HIV-1 in primary macrophages by reduction of surface expression of CD4, chemokine receptors CCR5, CXCR4 and post-entry viral gene expression. Eur. J. Immunol. 30 (2000) 1340-1349
23. Denis M., and Ghadirian E. Interleukin 13 and interleukin 4 protect bronchoalveolar macrophages from productive infection with human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 (1994) 795-802
24. Hatch W.C., Freedman A.R., Boldt-Houle D.M., Groopman J.E., and Terwilliger E.F. Differential effects of interleukin-13 on cytomegalovirus and human immunodeficiency virus infection in human alveolar macrophages. Blood 89 (1997) 3443-3450
25. Park J.W., Taube C., Yang E.S., Joetham A., Balhorn A., Takeda K., Miyahara N., Dakhama A., Donaldson D.D., and Gelfand E.W. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen. J. Allergy Clin. Immunol. 112 (2003) 1078-1087
26. Peebles Jr. R.S., Sheller J.R., Collins R.D., Jarzecka A.K., Mitchell D.B., Parker R.A., and Graham B.S. Respiratory syncytial virus infection does not increase allergen- induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. J. Med. Virol. 63 (2001) 178-188
27. Lukacs N.W., Moore M.L., Rudd B.D., Berlin A.A., Collins R.D., Olson S.J., Ho S.B., and Peebles Jr. R.S. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am. J. Pathol. 169 (2006) 977-986
28. Hilton D.J., Zhang J.G., Metcalf D., Alexander W.S., Nicola N.A., and Willson T.A. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 497-501
29. Zurawski G., and de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15 (1994) 19-26
30. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., and Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003) 1741-1752
31. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., and Berzofsky J.A. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13020-13025
32. Sharma D.P., Ramsay A.J., Maguire D.J., Rolph M.S., and Ramshaw I.A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 70 (1996) 7103-7107
33. Aung S., Tang Y.W., and Graham B.S. Interleukin-4 diminishes CD8(+) respiratory syncytial virus-specific cytotoxic T-lymphocyte activity in vivo. J. Virol. 73 (1999) 8944-8949
34. Aung S., and Graham B.S. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J. Immunol. 164 (2000) 3487-3493
35. LeVine A.M., Gwozdz J., Stark J., Bruno M., Whitsett J., and Korfhagen T. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J. Clin. Invest. 103 (1999) 1015-1021
36. LeVine A.M., Elliott J., Whitsett J.A., Srikiatkhachorn A., Crouch E., DeSilva N., and Korfhagen T. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol. 31 (2004) 193-199
37. Lanone S., Zheng T., Zhu Z., Liu W., Lee C.G., Ma B., Chen Q., Homer R.J., Wang J., Rabach L.A., Rabach M.E., Shipley J.M., Shapiro S.D., Senior R.M., and Elias J.A. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J. Clin. Invest. 110 (2002) 463-474
38. Yeo S.J., Yun Y.J., Lyu M.A., Woo S.Y., Woo E.R., Kim S.J., Lee H.J., Park H.K., and Kook Y.H. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch. Virol. 147 (2002) 229-242
39. Fulkerson P.C., Fischetti C.A., Hassman L.M., Nikolaidis N.M., and Rothenberg M.E. Persistent effects induced by IL-13 in the lung. Am. J. Respir. Cell Mol. Biol. 35 (2006) 337-346
40. Zavasnik-Bergant T., and Turk B. Cysteine cathepsins in the immune response. Tissue Antigens 67 (2006) 349-355
41. Qiu Z., Hingley S.T., Simmons G., Yu C., Das S.J., Bates P., and Weiss S.R. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J. Virol. 80 (2006) 5768-5776
42. Schornberg K., Matsuyama S., Kabsch K., Delos S., Bouton A., and White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80 (2006) 4174-4178